Use of pegylated recombinant human arginase for treatment of leukemia
AssigneeBio-Cancer Treatment International Limited
InventorNing Man Cheng
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid. In another embodiment, the leukemia is arsenic resistant. In a further embodiment, the arginase is pegylated recombinant human arginase. In another embodiment, the arginase can be administrated in combination with a second therapeutic agent such as Doxorubicin in the treatment of leukemia.
Claims14
A method of treating leukemia in a patient comprising administrating to the patient a therapeutically effective amount of a composition comprising arginase, wherein said composition is effective at treating lymphocytic and/or myeloid leukemia.
A method of treating cancer in a patient comprising administrating to the patient a therapeutically effective amount of a composition comprising arginase, wherein said patient suffers from relapsed or refractory leukemia or lymphoma.
Dependencies are inferred from the claim text.